From 1990 onwards, Johnson was one of the team at Cambridge Antibody Technology (CAT), heading up research and in 1997 he was appointed to the board, where he held the posts of Research Director and Chief Technology Officer. Kevin led both the development of CAT's platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development, including the first such drug, Humira to reach the market. He was also part of the management team that floated CAT on the London Stock Exchange (main market).
^"Home"(PDF). Scripintelligence. Archived from the original(PDF) on 2012-03-14. Retrieved 2012-07-31.
This page is based on a Wikipedia article written by authors
Text is available under the CC BY-SA 3.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.